Literature DB >> 29208074

The impact of implementing a Xpert MTB/RIF algorithm on drug-sensitive pulmonary tuberculosis: a retrospective analysis.

K Rees1, N Muditambi1, M Maswanganyi2, J Railton1, J A McIntyre1, H E Struthers1, P B Fourie3, R P H Peters1.   

Abstract

Xpert MTB/RIF (Xpert) is the preferred first-line test for all persons with tuberculosis (TB) symptoms in South Africa in line with a diagnostic algorithm. This study evaluates pre- and post-implementation trends in diagnostic practices for drug-sensitive, pulmonary TB in adults in an operational setting, following the introduction of the Xpert-based algorithm. We retrospectively analysed data from the national TB database for Greater Tzaneen sub-district, Limpopo Province. Trends in a number of cases, diagnosis and outcome and characteristics associated with death are reported. A total of 8407 cases were treated from 2008 until 2015, with annual cases registered decreasing by 31·7% over that time period (from 1251 to 855 per year). After implementation of Xpert, 69·9% of cases were diagnosed by Xpert, 29·4% clinically, 0·6% by smear microscopy and 0·1% by culture. Cases with a recorded microbiological test increased from 76·2% to 96·4%. Cases started on treatment without confirmation, but with a negative microbiological test increased from 7·1% to 25·7%. Case fatality decreased from 15·0% to 9·8%, remaining consistently higher in empirically treated groups, regardless of HIV status. Implementation of the algorithm coincided with a reduced number of TB cases treated and improved coverage of microbiological testing; however, a substantial proportion of cases continued to start treatment empirically.

Entities:  

Keywords:  Diagnostic trend; HIV; Xpert; tuberculosis

Mesh:

Substances:

Year:  2017        PMID: 29208074      PMCID: PMC9134741          DOI: 10.1017/S0950268817002746

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  23 in total

1.  Do adjunct tuberculosis tests, when combined with Xpert MTB/RIF, improve accuracy and the cost of diagnosis in a resource-poor setting?

Authors:  Grant Theron; Anil Pooran; Jonny Peter; Richard van Zyl-Smit; Hridesh Kumar Mishra; Richard Meldau; Greg Calligaro; Brian Allwood; Surendra Kumar Sharma; Rod Dawson; Keertan Dheda
Journal:  Eur Respir J       Date:  2011-11-10       Impact factor: 16.671

2.  Xpert MTB/RIF Results in Patients With Previous Tuberculosis: Can We Distinguish True From False Positive Results?

Authors:  Grant Theron; Rouxjeane Venter; Greg Calligaro; Liezel Smith; Jason Limberis; Richard Meldau; Duncan Chanda; Aliasgar Esmail; Jonny Peter; Keertan Dheda
Journal:  Clin Infect Dis       Date:  2016-02-16       Impact factor: 9.079

3.  Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial.

Authors:  Grant Theron; Lynn Zijenah; Duncan Chanda; Petra Clowes; Andrea Rachow; Maia Lesosky; Wilbert Bara; Stanley Mungofa; Madhukar Pai; Michael Hoelscher; David Dowdy; Alex Pym; Peter Mwaba; Peter Mason; Jonny Peter; Keertan Dheda
Journal:  Lancet       Date:  2013-10-28       Impact factor: 79.321

4.  Tuberculosis control in South Africa: successes, challenges and recommendations.

Authors:  G J Churchyard; L D Mametja; L Mvusi; N Ndjeka; A C Hesseling; A Reid; S Babatunde; Y Pillay
Journal:  S Afr Med J       Date:  2014-03

5.  Incidence of tuberculosis in HIV-infected patients before and after starting combined antiretroviral therapy in 8 sub-Saharan African HIV programs.

Authors:  Sarala Nicholas; Kalpana Sabapathy; Cecilia Ferreyra; Francis Varaine; Mar Pujades-Rodríguez
Journal:  J Acquir Immune Defic Syndr       Date:  2011-08-01       Impact factor: 3.731

6.  Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF.

Authors:  Gavin J Churchyard; Wendy S Stevens; Lerole D Mametja; Kerrigan M McCarthy; Violet Chihota; Mark P Nicol; Linda K Erasmus; Norbert O Ndjeka; Lindiwe Mvusi; Anna Vassall; Edina Sinanovic; Helen S Cox; Christopher Dye; Alison D Grant; Katherine L Fielding
Journal:  Lancet Glob Health       Date:  2015-08       Impact factor: 26.763

7.  Implementation and Operational Research: What Happens After a Negative Test for Tuberculosis? Evaluating Adherence to TB Diagnostic Algorithms in South African Primary Health Clinics.

Authors:  K M McCarthy; A D Grant; V Chihota; S Ginindza; L Mvusi; G J Churchyard; K L Fielding
Journal:  J Acquir Immune Defic Syndr       Date:  2016-04-15       Impact factor: 3.731

8.  The impact of the roll-out of rapid molecular diagnostic testing for tuberculosis on empirical treatment in Cape Town, South Africa.

Authors:  Sabine Hermans; Judy Caldwell; Richard Kaplan; Frank Cobelens; Robin Wood
Journal:  Bull World Health Organ       Date:  2017-04-28       Impact factor: 9.408

9.  Impact of replacing smear microscopy with Xpert MTB/RIF for diagnosing tuberculosis in Brazil: a stepped-wedge cluster-randomized trial.

Authors:  Betina Durovni; Valeria Saraceni; Susan van den Hof; Anete Trajman; Marcelo Cordeiro-Santos; Solange Cavalcante; Alexandre Menezes; Frank Cobelens
Journal:  PLoS Med       Date:  2014-12-09       Impact factor: 11.069

10.  Comparing Tuberculosis Diagnostic Yield in Smear/Culture and Xpert® MTB/RIF-Based Algorithms Using a Non-Randomised Stepped-Wedge Design.

Authors:  Pren Naidoo; Rory Dunbar; Carl Lombard; Elizabeth du Toit; Judy Caldwell; Anne Detjen; S Bertel Squire; Donald A Enarson; Nulda Beyers
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

View more
  1 in total

1.  Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  David J Horne; Mikashmi Kohli; Jerry S Zifodya; Ian Schiller; Nandini Dendukuri; Deanna Tollefson; Samuel G Schumacher; Eleanor A Ochodo; Madhukar Pai; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2019-06-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.